<DOC>
	<DOC>NCT00790114</DOC>
	<brief_summary>To determine the effects of repeated doses of AZD7325 on the pharmacokinetic profile of a CYP3A4 substrate (midazolam and its 1' hydroxy metabolite) and a CYP1A2 substrate (caffeine and its paraxanthine [3-desmethyl] metabolite).</brief_summary>
	<brief_title>Determine the Effect of Multiple Doses of AZD7325, CYP Study</brief_title>
	<detailed_description />
	<mesh_term>Caffeine</mesh_term>
	<mesh_term>Midazolam</mesh_term>
	<criteria>Clinically relevant abnormalities in physical examinations, vital signs, clinical chemistry, hematology or urinalysis as judged by the investigator and/or sponsor. Enrollment in another concurrent investigational study or intake of an investigational drug within 3 months or intake of an investigational drug within a period of 5 half lives of that drug prior to the screening visit</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>November 2008</verification_date>
	<keyword>Phase I</keyword>
</DOC>